https://rijournals.com/research-in-medical-sciences/

RESEARCH INVENTION JOURNAL OF RESEARCH IN MEDICAL SCIENCES 4(3):59-64, 2025

ONLINE ISSN: 1115- 6198

Print ISSN: 1597-3107

https://doi.org/10.59298/RIJRMS/2025/435964

Antioxidant-Loaded Nanoparticles as Therapeutic Tools for Oxidative Stress in Obesity and Diabetes

Bwensiyo Twebaza H.

Faculty of Science and Technology Kampala International University Uganda

ABSTRACT

Obesity and diabetes mellitus are chronic metabolic disorders characterized by systemic oxidative stress, contributing to cellular dysfunction, inflammation, and disease progression. The imbalance between reactive oxygen species (ROS) production and antioxidant defenses leads to significant damage in pancreatic β-cells, insulin signaling pathways, and adipose tissue. Conventional antioxidant therapies are often limited by poor bioavailability, instability, and lack of targeted delivery. Nanotechnology offers a promising platform for the development of antioxidant-loaded nanoparticles (NPs), providing improved solubility, enhanced bioavailability, controlled release, and site-specific targeting. This review critically examines the recent advancements in the design, synthesis, and application of antioxidant-loaded nanoparticles, such as polymeric nanoparticles, lipid-based carriers, metal oxide nanoparticles, and dendrimers, in mitigating oxidative stress associated with obesity and diabetes. We also explore their mechanisms of action, therapeutic efficacy in preclinical models, and translational potential. Finally, we highlight current challenges and future perspectives in optimizing nanocarrier systems for clinical use in metabolic disease management.

Keywords: Antioxidants, Nanoparticles, Oxidative Stress, Obesity, Diabetes Mellitus, Nanoformulations, Reactive Oxygen Species, Drug Delivery

INTRODUCTION

Obesity and diabetes mellitus are major public health concerns globally, with their prevalence escalating at an alarming rate due to factors such as sedentary lifestyles, unhealthy dietary patterns, urbanization, and genetic susceptibility[1–5]. Obesity, often characterized by excess adipose tissue accumulation, is a primary risk factor for type 2 diabetes mellitus (T2DM), a chronic metabolic disorder marked by insulin resistance and hyperglycemia. Both conditions are interrelated and frequently co-exist, forming a pathological loop that complicates prevention and treatment strategies[6–9]. The underlying mechanisms of obesity and diabetes are multifactorial, but chronic low-grade inflammation and oxidative stress have been identified as central contributors to their onset and progression[10]. Oxidative stress results from an imbalance between the excessive generation of reactive oxygen species (ROS) and the body's capacity to neutralize them using intrinsic antioxidant defense systems[11, 12]. This oxidative imbalance damages cellular components including lipids, proteins, and DNA, thereby exacerbating metabolic dysfunction and increasing the risk of complications such as cardiovascular diseases, neuropathy, nephropathy, and retinopathy[13].

In response to oxidative stress, the body utilizes both enzymatic antioxidants (e.g., superoxide dismutase, catalase, glutathione peroxidase) and non-enzymatic antioxidants (e.g., vitamin C, vitamin E, polyphenols) to mitigate the harmful effects of ROS[14, 15]. Despite the potential benefits of antioxidant supplementation in ameliorating oxidative damage, conventional antioxidant therapies face several limitations. These include poor aqueous solubility, instability under physiological conditions, rapid metabolic degradation, and inadequate tissue distribution, all of which limit their clinical utility. As a result, there is a growing interest in exploring innovative delivery strategies that can overcome these pharmacokinetic hurdles and enhance therapeutic outcomes. The field of nanomedicine, particularly the use of nanoparticle-based delivery systems, offers a promising approach to address these challenges. By encapsulating antioxidants within biocompatible nanoparticles, it is possible to improve their stability, control their release, and enhance their cellular uptake and bioavailability[16, 17].

Nanotechnology has emerged as a powerful tool in modern biomedical research, enabling the development of sophisticated delivery platforms that can target oxidative stress at the molecular level[18, 19]. Antioxidant-loaded nanoparticles—such as liposomes, polymeric nanoparticles, dendrimers, and solid lipid nanoparticles—are being extensively studied for their ability to protect antioxidants from premature degradation, prolong their circulation time, and facilitate their targeted delivery to sites of inflammation or oxidative damage[16, 20–22]. These nanoformulations can be engineered to respond to specific physiological stimuli, such as pH changes or oxidative environments, ensuring a more precise and effective intervention. Furthermore, their small size and surface modifiability allow them to penetrate biological barriers and achieve higher intracellular concentrations of antioxidants, which is particularly advantageous in managing obesity- and diabetes-related complications. Current research has shown promising results in both in vitro and in vivo models, highlighting the potential of nanotechnology-based antioxidant therapies to revolutionize the management of metabolic disorders.[23–25] As the burden of obesity and diabetes continues to grow, advancing these novel therapeutic strategies is essential for improving patient outcomes and reducing the global health impact of these interlinked diseases.

Oxidative Stress in Obesity and Diabetes

Pathophysiological Role of ROS

Reactive oxygen species (ROS) play a central role in the development and progression of obesity and diabetes by mediating oxidative stress, which results from an imbalance between ROS production and antioxidant defenses[26]. In obesity, the expansion of adipose tissue leads to the hypertrophy of adipocytes, which become dysfunctional and produce elevated levels of ROS such as superoxide anion and hydrogen peroxide. These reactive molecules activate pro-inflammatory signaling pathways, including NF-κB and JNK, leading to chronic low-grade inflammation—a hallmark of obesity[27]. This inflammation further exacerbates insulin resistance by impairing insulin receptor signaling and promoting the release of pro-inflammatory cytokines such as TNF-α and IL-6. In type 2 diabetes mellitus (T2DM), chronic hyperglycemia and elevated free fatty acids increase mitochondrial ROS production in insulin-sensitive tissues, including the liver, muscle, and adipose tissue. ROS interfere with insulin signaling by oxidizing key signaling proteins, disrupting GLUT4 translocation, and impairing glucose uptake. Moreover, in pancreatic β-cells, which possess inherently low antioxidant defenses, elevated ROS levels damage cellular structures, impair insulin synthesis, and promote apoptosis[27, 28]. This leads to a progressive decline in β-cell function, a defining feature of T2DM. Thus, ROS contribute significantly to both the initiation and perpetuation of metabolic dysfunction in obesity and diabetes.

Biomarkers of Oxidative Stress

The assessment of oxidative stress in obesity and diabetes is crucial for understanding disease progression, identifying therapeutic targets, and monitoring treatment efficacy[29]. Several biomarkers have been identified to quantify oxidative damage and antioxidant capacity in individuals with metabolic disorders. One of the most commonly used biomarkers is malondialdehyde (MDA), a by-product of lipid peroxidation, which reflects oxidative damage to cell membranes[9, 30]. Elevated MDA levels are frequently reported in obese and diabetic individuals and are correlated with increased disease severity. Another key biomarker is 8-hydroxydeoxyguanosine (8-OHdG), a marker of oxidative DNA damage. High levels of 8-OHdG in blood or urine suggest enhanced ROS-induced genomic instability, which may contribute to complications such as diabetic nephropathy and cardiovascular disease. Reduced glutathione (GSH), a major endogenous antioxidant, is often depleted under oxidative stress conditions[31]. Low GSH levels are indicative of impaired antioxidant defense and heightened susceptibility to oxidative damage. Additional biomarkers include protein carbonyls (for protein oxidation), nitric oxide derivatives, and enzymatic antioxidants such as superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPx)[32]. A comprehensive analysis of these markers can provide a detailed oxidative profile of patients, helping to tailor antioxidant interventions and improve outcomes in obesity- and diabetes-related complications.

Limitations of Conventional Antioxidant Therapies

Despite the promising theoretical benefits of antioxidants in mitigating oxidative stress, conventional antioxidant therapies have shown limited clinical efficacy in the management of obesity and diabetes. Common antioxidant supplements, including vitamins C and E, flavonoids, and polyphenolic compounds such as resveratrol and quercetin, have demonstrated beneficial effects in preclinical studies; however, their translation to human studies has been inconsistent and often disappointing[33]. One major limitation is poor bioavailability—many of these compounds have low solubility in water or are rapidly metabolized and eliminated, resulting in subtherapeutic concentrations at target sites. Additionally, many antioxidants are unstable in the gastrointestinal (GI) environment, undergoing degradation before they can exert their effects. Another issue is nonspecific distribution: once absorbed, antioxidants circulate systemically and may not accumulate sufficiently in the tissues most affected by oxidative stress, such as adipose tissue, pancreatic islets, or the vascular endothelium [34]. Moreover, excessive or inappropriate antioxidant supplementation may paradoxically disrupt redox signaling and impair cellular defense mechanisms[35]. These limitations highlight the urgent need for advanced delivery systems that can improve antioxidant stability, enhance absorption, and

enable targeted delivery. Strategies such as nanoparticle-based delivery, liposomal encapsulation, and prodrug formulations are being explored to overcome these barriers and maximize the therapeutic potential of antioxidant therapy in metabolic disorders.

Nanoparticle-Based Antioxidant Delivery Systems

Nanoparticle-based antioxidant delivery systems present a revolutionary approach to enhancing the therapeutic efficacy of antioxidants, especially in the management of oxidative stress-related metabolic disorders. One of the primary advantages of nanoparticles is their ability to improve the solubility and stability of antioxidant compounds, many of which are poorly water-soluble[36]. This increased bioavailability ensures that the antioxidants remain active for longer periods in physiological environments. Moreover, nanoparticles offer targeted and sustained release profiles, minimizing systemic side effects and optimizing therapeutic outcomes[36]. They also protect antioxidants from enzymatic degradation and harsh gastrointestinal conditions, thereby preserving their bioactivity. Additionally, nanoparticles facilitate enhanced cellular uptake, ensuring that therapeutic agents reach their intracellular targets more effectively. Several types of antioxidant-loaded nanoparticles have been developed. Polymeric nanoparticles, particularly those utilizing PLGA and chitosan, have demonstrated success in encapsulating compounds such as resveratrol, curcumin, and quercetin, resulting in prolonged activity and improved bioefficacy. Lipid-based carriers, including liposomes and solid lipid nanoparticles, are especially suitable for hydrophobic antioxidants like vitamin E and curcumin, effectively reducing oxidative stress in diabetic models[37]. Metal oxide nanoparticles, such as cerium oxide and zinc oxide, act as nanozymes with intrinsic antioxidant properties, mimicking enzymatic activity to neutralize reactive oxygen species (ROS).

Dendrimers and nanomicelles represent more advanced nanocarrier systems, offering superior surface functionality and the potential for precise control over drug release kinetics. These carriers can be engineered to load multiple antioxidant molecules and tailored with surface modifications for targeted delivery to specific tissues or cell types[38]. Mechanistically, antioxidant-loaded nanoparticles exert their therapeutic effects through several pathways. They directly scavenge ROS such as superoxide anions, hydroxyl radicals, and hydrogen peroxide, thereby mitigating oxidative damage. Furthermore, they exhibit anti-inflammatory properties by inhibiting key signaling pathways, including nuclear factor-kappa B (NF-κB), thus reducing the expression of pro-inflammatory cytokines. Antioxidant nanoparticles also protect mitochondria from dysfunction and apoptosis, crucial for maintaining energy metabolism and cellular integrity. In metabolic disorders like diabetes, these nanoparticles enhance insulin signaling by modulating insulin receptor substrate (IRS-1), phosphoinositide 3-kinase (PI3K), and Akt pathways, ultimately improving insulin sensitivity[16]. Preclinical studies in animal models have provided encouraging results, with formulations like curcumin-PLGA nanoparticles lowering fasting glucose and oxidative stress, while quercetin-loaded SLNs enhanced insulin responsiveness. Although clinical applications are still emerging, preliminary trials indicate promise for treating metabolic syndrome and diabetic complications. Continued research is essential to determine optimal dosing, safety profiles, and long-term outcomes of nanoparticle-based antioxidant therapies.

Challenges and Future Directions

One of the primary challenges in the development of antioxidant-loaded nanoparticles for therapeutic use in obesity and diabetes is the concern surrounding their long-term safety and toxicity, especially those composed of inorganic materials such as metal-based nanoparticles (e.g., gold, silver, or cerium oxide). Although these nanostructures offer unique physicochemical properties that enhance antioxidant activity and enable targeted delivery, their potential to induce cytotoxicity, immunogenic responses, and organ accumulation remains a pressing concern. Chronic exposure could lead to unforeseen side effects that may compromise patient safety. Moreover, the interaction of nanoparticles with biological systems can be highly complex, involving protein corona formation, oxidative degradation, or unintended immune activation. Thorough in vivo toxicological assessments, long-term biodistribution studies, and detailed pharmacokinetic profiling are critical to understanding the safety implications of these nanoformulations. Additionally, ethical concerns about the use of engineered nanomaterials in vulnerable populations such as individuals with metabolic syndromes must be considered. To address these challenges, the development of biodegradable, biocompatible nanoparticles using natural or polymeric materials is gaining traction, with a focus on minimizing toxicity while preserving therapeutic efficacy.

Another major obstacle lies in the regulatory and manufacturing domains. Currently, the clinical translation of nanomedicines is hampered by the lack of standardized protocols for nanoparticle synthesis, scale-up, and quality assurance. Variability in particle size, surface properties, and encapsulation efficiency during large-scale production can affect therapeutic performance and reproducibility, leading to inconsistent outcomes. Regulatory agencies, including the FDA and EMA, are still developing comprehensive frameworks to evaluate nanomedicine safety, efficacy, and manufacturing quality. Without clear regulatory guidelines, the approval and commercialization of antioxidant-loaded nanoparticles may face significant delays. To facilitate progress, collaborative efforts between academia, industry, and regulatory bodies are necessary to establish robust

standard operating procedures, GMP-compliant manufacturing practices, and consensus-based guidelines for nanoparticle characterization. Furthermore, advancements in process analytical technologies (PAT) and real-time monitoring tools can help ensure batch-to-batch consistency and streamline clinical development pipelines. Addressing these regulatory and manufacturing bottlenecks is essential for translating promising laboratory findings into clinically viable therapies.

CONCLUSION

Antioxidant-loaded nanoparticles have emerged as a transformative therapeutic strategy for mitigating oxidative stress in metabolic disorders such as obesity and diabetes. These nanoformulations offer several advantages over conventional antioxidant therapies, including enhanced bioavailability, controlled release profiles, targeted tissue delivery, and the ability to cross physiological barriers such as the gastrointestinal tract or cellular membranes. By directly scavenging reactive oxygen species (ROS) and modulating redox-sensitive signaling pathways, these nanoparticles can effectively reduce systemic oxidative stress, improve insulin sensitivity, and attenuate inflammation. All of which are critical in the pathophysiology of obesity-related complications. Moreover, their ability to co-deliver multiple therapeutic agents (e.g., antioxidants with anti-inflammatory or hypoglycemic drugs) provides an integrated approach for addressing the multifactorial nature of metabolic diseases. Preclinical studies using in vitro cell models and in vivo animal systems have consistently demonstrated the potential of these nanocarriers to restore redox homeostasis and improve metabolic outcomes, laying a strong foundation for future clinical research.

Despite these encouraging advances, the path toward clinical implementation of antioxidant-loaded nanoparticles remains complex and demands sustained interdisciplinary collaboration. There is a growing recognition of the need for personalized nanomedicine approaches, where therapies are tailored based on an individual's oxidative stress profile, genetic background, and metabolic status. Innovations in biosensors and wearable devices for real-time oxidative stress monitoring could facilitate this personalization, enabling clinicians to administer the right formulation at the right dose and time. Future research should also explore smart or stimuli-responsive nanoparticles that release their cargo in response to redox changes in the microenvironment, thereby enhancing therapeutic precision and minimizing side effects. Integrating nanotechnology with systems biology, bioinformatics, and machine learning will further accelerate the design of next-generation therapeutics. In conclusion, while numerous scientific, technical, and regulatory challenges persist, the potential of antioxidant-loaded nanoparticles in revolutionizing the management of obesity and diabetes is immense and worth pursuing through concerted global research efforts.

REFERENCES

1. Aloo, S.O., Barathikannan, K., Oh, D.-H.: Polyphenol-rich fermented hempseed ethanol extracts improve obesity, oxidative stress, and neural health in high-glucose diet-induced *Caenorhabditis elegans*. Food Chem. X. 21, 101233 (2024). https://doi.org/10.1016/j.fochx.2024.101233
2. Alum, E.U.: Metabolic memory in obesity: Can early-life interventions reverse lifelong risks? Obes. Med. 55, 100610 (2025). https://doi.org/10.1016/j.obmed.2025.100610
3. Uti, D.E., Atangwho, I.J., Omang, W.A., Alum, E.U., Obeten, U.N., Udeozor, P.A., Agada, S.A., Bawa, I., Ogbu, C.O.: Cytokines as key players in obesity low grade inflammation and related complications. Obes. Med. 54, 100585 (2025). https://doi.org/10.1016/j.obmed.2025.100585
4. Ansari, P., Akther, S., Hannan, J.M.A., Seidel, V., Nujat, N.J., Abdel-Wahab, Y.H.A.: Pharmacologically Active Phytomolecules Isolated from Traditional Antidiabetic Plants and Their Therapeutic Role for the Management of Diabetes Mellitus. Molecules. 27, 4278 (2022). https://doi.org/10.3390/molecules27134278
5. Uti, D.E., Atangwho, I.J., Alum, E.U., Egba, S.I., Ugwu, O.P.-C., Ikechukwu, G.C.: Natural Antidiabetic Agents: Current Evidence and Development Pathways from Medicinal Plants to Clinical use. Nat. Prod. Commun. 20, 1934578X251323393 (2025). https://doi.org/10.1177/1934578X251323393
6. Umoru, G.U., Atangwho, I.J., David-Oku, E., Uti, D.E., Agwupuye, E.I., Obeten, U.N., Maitra, S., Subramaniyan, V., Wong, L.S., Aljarba, N.H., Kumarasamy, V.: Tetracarpidium conophorum nuts (African walnuts) up-regulated adiponectin and PPAR-γ expressions with reciprocal suppression of TNF-α gene in obesity. J. Cell. Mol. Med. 28, e70086 (2024). https://doi.org/10.1111/jcmm.70086
7. Annett, S., Moore, G., Robson, T.: Obesity and Cancer Metastasis: Molecular and Translational Perspectives. Cancers. 12, 3798 (2020). https://doi.org/10.3390/cancers12123798
8. Uti, D.E., Atangwho, I.J., Eyong, E.U., Umoru, G.U., Egbung, G.E., Rotimi, S.O., Nna, V.U.: African walnuts (Tetracarpidium conophorum) modulate hepatic lipid accumulation in obesity via reciprocal actions on HMG-CoA reductase and paraoxonase. Endocr. Metab. Immune Disord.-Drug Targets Former. Curr. Drug Targets-Immune Endocr. Metab. Disord. 20, 365–379 (2020)
9. Uti, D.E., Atangwho, I.J., Eyong, E.U., Umoru, G.U., Egbung, G.E., Nna, V.U., Udeozor, P.A.: African walnuts attenuate ectopic fat accumulation and associated peroxidation and oxidative stress in

monosodium glutamate-obese Wistar rats. Biomed. Pharmacother. Biomedecine Pharmacother. 124, 109879 (2020). https://doi.org/10.1016/j.biopha.2020.109879

10. Górczyńska-Kosiorz, S., Kosiorz, M., Dzięgielewska-Gęsiak, S.: Exploring the Interplay of Genetics and Nutrition in the Rising Epidemic of Obesity and Metabolic Diseases. Nutrients. 16, 3562 (2024). https://doi.org/10.3390/nu16203562
11. Alves, I., Araújo, E.M.Q., Dalgaard, L.T., Singh, S., Børsheim, E., Carvalho, E.: Protective Effects of Sulforaphane Preventing Inflammation and Oxidative Stress to Enhance Metabolic Health: A Narrative Review. Nutrients. 17, 428 (2025). https://doi.org/10.3390/nu17030428
12. Alum, E.U.: Antioxidant Effect Of Buchholzia Coriacea Ethanol Leaf-Extract and Fractions On Freund's Adjuvant-Induced Arthritis In Albino Rats: A Comparative Study. Slov. Vet. Res. 59, (2022). https://doi.org/10.26873/SVR-1150-2022
13. Agada, S.A., Odama, R.I., Kenechukwu, C.O., Aondoaseer, K., Ezeh, C.O., Uti, D.E., Alum, E.U.: Antioxidant and hepatoprotective effects of methanolic seed extract of Telfairia occidentalis on carbon tetrachloride induced hepatic damage in wistar rats. Discov. Med. 1, 75 (2024). https://doi.org/10.1007/s44337-024-00096-6
14. Aja, P., Alum, E., Ominyi, M., Chinyere, A., Ekpono, E.: Amino Acid Profile, Vitamin and Reducing Sugar Compositions Of Ethanol Fruit-Extract Of Phoenix dactylifera L (Date Fruit) Sold In Abakaliki, Ebonyi State, Nigeria. 6, 349–362 (2017)
15. Rudenko, N.N., Vetoshkina, D.V., Marenkova, T.V., Borisova-Mubarakshina, M.M.: Antioxidants of Non-Enzymatic Nature: Their Function in Higher Plant Cells and the Ways of Boosting Their Biosynthesis. Antioxidants. 12, 2014 (2023). https://doi.org/10.3390/antiox12112014
16. Uti, D.E., Atangwho, I.J., Alum, E.U., Ntaobeten, E., Obeten, U.N., Bawa, I., Agada, S.A., Ukam, C.I.-O., Egbung, G.E.: Antioxidants in cancer therapy mitigating lipid peroxidation without compromising treatment through nanotechnology. Discov. Nano. 20, 70 (2025). https://doi.org/10.1186/s11671-025-04248-0
17. Uti, D.E., Alum, E.U., Atangwho, I.J., Ugwu, O.P.-C., Egbung, G.E., Aja, P.M.: Lipid-based nano-carriers for the delivery of anti-obesity natural compounds: advances in targeted delivery and precision therapeutics. J. Nanobiotechnology. 23, 336 (2025). https://doi.org/10.1186/s12951-025-03412-z
18. Alghamdi, M.A., Fallica, A.N., Virzì, N., Kesharwani, P., Pittalà, V., Greish, K.: The Promise of Nanotechnology in Personalized Medicine. J. Pers. Med. 12, 673 (2022). https://doi.org/10.3390/jpm12050673
19. Ebrahimi, N., Manavi, M.S., Nazari, A., Momayezi, A., Faghihkhorasani, F., Rasool Riyadh Abdulwahid, A.-H., Rezaei-Tazangi, F., Kavei, M., Rezaei, R., Mobarak, H., Aref, A.R., Fang, W.: Nano-scale delivery systems for siRNA delivery in cancer therapy: New era of gene therapy empowered by nanotechnology. Environ. Res. 239, 117263 (2023). https://doi.org/10.1016/j.envres.2023.117263
20. Chehelgerdi, M., Chehelgerdi, M., Allela, O.Q.B., Pecho, R.D.C., Jayasankar, N., Rao, D.P., Thamaraikani, T., Vasanthan, M., Viktor, P., Lakshmaiya, N., Saadh, M.J., Amajd, A., Abo-Zaid, M.A., Castillo-Acobo, R.Y., Ismail, A.H., Amin, A.H., Akhavan-Sigari, R.: Progressing nanotechnology to improve targeted cancer treatment: overcoming hurdles in its clinical implementation. Mol. Cancer. 22, 169 (2023). https://doi.org/10.1186/s12943-023-01865-0
21. Kumarasamy, R.V., Natarajan, P.M., Umapathy, V.R., Roy, J.R., Mironescu, M., Palanisamy, C.P.: Clinical applications and therapeutic potentials of advanced nanoparticles: a comprehensive review on completed human clinical trials. Front. Nanotechnol. 6, (2024). https://doi.org/10.3389/fnano.2024.1479993
22. Jalili, A., Bagherifar, R., Nokhodchi, A., Conway, B., Javadzadeh, Y.: Current Advances in Nanotechnology-Mediated Delivery of Herbal and Plant-Derived Medicines. Adv. Pharm. Bull. 13, 712–722 (2023). https://doi.org/10.34172/apb.2023.087
23. Sinitsyna, V.V., Vetcher, A.A.: Nucleic Acid Aptamers in Nanotechnology. Biomedicines. 10, 1079 (2022). https://doi.org/10.3390/biomedicines10051079
24. Nanotechnology-Abetted Astaxanthin Formulations in Multimodal Therapeutic and Biomedical Applications. J. Med. Chem. 65, 2–36 (2022). https://doi.org/10.1021/acs.jmedchem.1c01144
25. Heydari, S., Masoumi, N., Esmaeeli, E., Ayyoubzadeh, S.M., Ghorbani-Bidkorpeh, F., Ahmadi, M.: Artificial intelligence in nanotechnology for treatment of diseases. J. Drug Target. 32, 1247–1266 (2024). https://doi.org/10.1080/1061186X.2024.2393417
26. Caturano, A., D'Angelo, M., Mormone, A., Russo, V., Mollica, M.P., Salvatore, T., Galiero, R., Rinaldi, L., Vetrano, E., Marfella, R., Monda, M., Giordano, A., Sasso, F.C.: Oxidative Stress in Type 2 Diabetes: Impacts from Pathogenesis to Lifestyle Modifications. Curr. Issues Mol. Biol. 45, 6651–6666 (2023). https://doi.org/10.3390/cimb45080420

27. Afzal, S., Abdul Manap, A.S., Attiq, A., Albokhadaim, I., Kandeel, M., Alhojaily, S.M.: From imbalance to impairment: the central role of reactive oxygen species in oxidative stress-induced disorders and therapeutic exploration. Front. Pharmacol. 14, 1269581 (2023). https://doi.org/10.3389/fphar.2023.1269581
28. Alum, E.U., Ikpozu, E.N., Offor, C.E., Igwenyi, I.O., Obaroh, I.O., Ibiam, U.A., Ukaidi, C.U.A.: RNA-based diagnostic innovations: A new frontier in diabetes diagnosis and management. Diab. Vasc. Dis. Res. 22, 14791641251334726 (2025). https://doi.org/10.1177/14791641251334726
29. Aravapally, P.S.N., Chandrasekar, Naveen, Verma , Arvind, and Shah, R.P.: Strategic approaches to assess and quantify the oxidative stress biomarkers in complex biological systems. Bioanalysis. 0, 1–14. https://doi.org/10.1080/17576180.2025.2486929
30. Udeozor, P.A., Ibiam, U.A., Uti, D.E., Umoru, G.U., Onwe, E.N., Mbonu, F.O., Omang, W.A., Ijoganu, S.I., Anaga, C.O., Mbah, J.O., Nwadum, S.K.: Antioxidant and Anti-Anemic Effects of Ethanol Leaf Extracts of Mucuna poggei and Telfairia occidentalis in Phenyl-Hydrazine-Induced Anemia in Wistar Albino Rats. Ibnosina J. Med. Biomed. Sci. 14, 116–126 (2022). https://doi.org/10.1055/s-0042-1756684
31. Goriuc, A., Cojocaru, K.-A., Luchian, I., Ursu, R.-G., Butnaru, O., Foia, L.: Using 8-Hydroxy-2′-Deoxiguanosine (8-OHdG) as a Reliable Biomarker for Assessing Periodontal Disease Associated with Diabetes. Int. J. Mol. Sci. 25, 1425 (2024). https://doi.org/10.3390/ijms25031425
32. S, S., Hegde, S.V., Agarwal, S.V., Ns, D., Pillai, A., Shah, S.N., S, R., S, S., Hegde, S.V., Agarwal, S.V., Ns, D., Pillai, D.A., Shah, S.N., S, R.: Biomarkers of Oxidative Stress and Their Clinical Relevance in Type 2 Diabetes Mellitus Patients: A Systematic Review. Cureus. 16, (2024). https://doi.org/10.7759/cureus.66570
33. Abdali, D., Samson, S.E., Grover, A.K.: How effective are antioxidant supplements in obesity and diabetes? Med. Princ. Pract. Int. J. Kuwait Univ. Health Sci. Cent. 24, 201–215 (2015). https://doi.org/10.1159/000375305
34. Alum, E.U., Udechukwu, C.D., Obasi, D.C.: RNA signaling in medicinal plants: An overlooked mechanism for phytochemical regulation. Biochem. Biophys. Rep. 42, 102032 (2025). https://doi.org/10.1016/j.bbrep.2025.102032
35. Price, G., Patel, D.A.: Drug Bioavailability. In: StatPearls. StatPearls Publishing, Treasure Island (FL) (2025)
36. Daré, R.G., Lautenschlager, S.O.S.: Nanoparticles with Antioxidant Activity. Antioxidants. 14, 221 (2025). https://doi.org/10.3390/antiox14020221
37. Gómez-Guillén, M.C., Montero, M.P.: Enhancement of oral bioavailability of natural compounds and probiotics by mucoadhesive tailored biopolymer-based nanoparticles: A review. Food Hydrocoll. 118, 106772 (2021). https://doi.org/10.1016/j.foodhyd.2021.106772
38. Zhu, Y., Liu, C., Pang, Z.: Dendrimer-Based Drug Delivery Systems for Brain Targeting. Biomolecules. 9, 790 (2019). https://doi.org/10.3390/biom9120790

CITE AS: Bwensiyo Twebaza H. (2025). Antioxidant-Loaded Nanoparticles as Therapeutic Tools for Oxidative Stress in Obesity and Diabetes. RESEARCH INVENTION JOURNAL OF RESEARCH IN MEDICAL SCIENCES 4(3):59-64. https://doi.org/10.59298/RIJRMS/2025/435964